FORMULATING FOR MICRONEEDLE DELIVERY. Professor Finn Bauer
|
|
- Horace Woods
- 5 years ago
- Views:
Transcription
1 FORMULATING FOR MICRONEEDLE DELIVERY Professor Finn Bauer
2 OVERVIEW Conventional microneedle strategies Change of mind set to consider systemic delivery of therapeutic agents Design & manufacture considerations Dissolving microneedles Hydrogel-forming microneedles Regulatory & clinical considerations Commercial development plan & patient benefit
3 CONVENTIONAL MICRONEEDLE APPLICATIONS Intradermal vaccines Local drug delivery Systemic administration of potent drugs Dissolving microneedles Coated microneedles Typically small patch sizes
4 EFFECTIVE IN VIVO DELIVERY OF NANOPARTICLE VACCINES Rapid Dissolvability In Situ 0 min 1 min 5 min min min Base Plate Rhodamine-NP DAPI Rhodamine NPs Optical Coherence Tomography in vivo OVA NP or bnp 21 days i.n. Sendai Virus Infection 10 days Not vaccinated Vaccinated bnp OVA NP or bnp 7 days B16-OVA Melanoma 13 days OVA NP
5 Blood glucose level (% of initial) EFFECTIVE INSULIN DELIVERY IN VIVO time (h) G20%-10 mg G20%-2.5 mg G20%-control
6 INDICATIONS FOR SYSTEMIC DRUG DELIVERY Potential to improve bioavailability Reduction of side-effects Sustainable drug delivery Bypass of the gastrointestinal tract Patient acceptability Patient and healthcare worker safety Co-administration of several drugs Regular patient use
7 CONSIDERATIONS FOR SYSTEMIC DRUG DELIVERY Most drugs are not of high potency Tens or hundreds of mg per day required Microneedle patch size Patient application Implications of repeat application Cost considerations Competitive advantages for industry Considerable benefits for patients
8 HIGH-LOADING DISSOLVING MICRONEEDLES 600 µm T 0 T 30 s T 5 min T 15 min Loading of 50% w/w drug Use biodegradable or low MW polymer Polymer must be good film former and have low Tg Dry slowly to promote physical stability Microneedle and patch design will influence deliverable dose Dissolution characteristics will affect duration of delivery Polymer MW and drug properties will determine whether baseplate delivery is appreciable Manufacture must be carried out in a low bioburden environment as a minimum
9 DELIVERY OF FIXED-DOSE COMBINATIONS IN VITRO Patch size for 24 hours delivery = 6 cm 2
10 Delivery of clinically-relevant doses of non-potent drugs in vivo Ibuprofen sodium (µg/ml) Occlusive backing layer Ibuprofen sodium-loaded microneedle array Adhesive foam Shaved area of rat skin Ibuprofen sodiumloaded baseplate Time (min) Patch size for 24 hours delivery = 10 cm 2
11 DISSOLVING MICRONEEDLES Self-disabling Effective in vivo delivery of insulin, vaccines and nanoparticles Sustained delivery of clinically-relevant amounts of small molecule non-potent drugs in vivo Reasonable patch sizes Deposit 5-10 mg polymer per cm 2 in skin Damaged by heat/steam sterilisation Gamma sterilisation alters release profiles and may cause drug degradation or chemical binding to polymer Manufacture in a low bioburden environment
12 HYDROGEL-FORMING MICRONEEDLES Microneedles contain no drug themselves Drug contained in a separate drug reservoir Microneedles are chemically crosslinked Rapid uptake of skin interstitial fluid Drug diffuses through swollen microneedles Rate of drug delivery determined by crosslink density Reservoir properties can be altered to modulate drug delivery Potential for higher doses and more prolonged delivery
13 % original BGL IN VIVO INSULIN: DIABETIC RAT MODEL Time (h) MN Patch
14 METRONIDAZOLE DELIVERY IN VIVO Patch size for 48 hours delivery = 10 cm 2
15 DONEPEZIL DELIVERY IN VIVO Patch size for 24 hours delivery = 30 cm 2
16 Ibuprofen-sodium ( g/ml) IBUPROFEN DELIVERY IN VIVO Patch size for 24 hours delivery = 30 cm Time (h)
17 Bevacizumab permeation (µg) Bevacizumab concentration (ng/ml) ANTIBODY DELIVERY IN VITRO AND IN VIVO High dose + MN Low dose + MN High dose Control Time (Minutes) 10 1 High dose Low dose IV dose Time (hours)
18 HYDROGEL-FORMING MICRONEEDLES Self-disabling, but removed intact No polymer deposition in skin Sustainable in vivo delivery of insulin Delivery not limited by what can be loaded into needles themselves Delivery rate controllable by simple adjustment of hydrogel properties Sterilisable without affecting properties Selection of drug reservoir can enhance delivery of high-dose small medicines. Differing pharmacokinetic pattern for very large biomolecules: Potential for lymphatic targeting
19 900 m PATIENT USE 400 m 600 m
20 CONFIRMING CORRECT INSERTION Outcome measures With pressure indicating sensor film Consent form Red impression 600 µm Press firmly for 30 sec No preference 15% Questionnaire Microneedle patch without pressure indicating sensor film 10% Microneedle patch with pressure indicating sensor film 75%
21 APPLICATION OF LARGE PATCHES
22 SKIN APPEARANCE & BARRIER FUNCTION Skin appearance unchanged relative to control No evidence of polymer accumulation in skin Skin barrier function unchanged relative to control
23 IMMUNE RESPONSE No measurable increase in IgG relative to control Needle density had no detectable effect No significant difference between dissolving and hydrogelforming microneedles
24 INFLAMMATION No measurable increase in IL-1 relative to control Needle density had no detectable effect Low ph of Gantrez S-97 formulation had no significant impact
25 INFECTION No measurable increase in C-reactive protein relative to control No increases in body temperature No significant changes in weight of the animals
26 CONCLUSION & NEXT STEPS Microneedles have great potential for delivery of therapeutics De-risk delivery platforms in accordance with regulatory advice Develop a bridging programme applicable to any drug to be delivered Manufacturing scale-up Licensing of manufacture Clinical studies Commercialisation and patient benefit
27
IIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES
IIS INNOVATIVE INJECTION SYSTEMS NEW PERSPECTIVES, MORE POSSIBILITIES IIS REVOLUTIONARY ADMINISTRATION TECHNIQUES MORE EFFICIENCY AND SAFETY IIS researches and develops innovative injection systems. Within
More informationApplications of self-assembling peptides in controlled drug delivery
Applications of self-assembling peptides in controlled drug delivery Sotirios Koutsopoulos, Ph.D. Problems associated with drug administration Drug concentration in blood C toxic C effective Time 1 The
More informationDrug Delivery Systems. Joab Chen & Kenneth Tsang
Drug Delivery Systems Joab Chen & Kenneth Tsang Drug Delivery How do we physically get drugs into our bodies? What are the various systems that are in use today? In the future? We as a class will determine
More informationNanosystems in regenerative medicine. Jöns Hilborn Materials Chemistry The Ångström Laboratory Uppsala University Sweden
Nanosystems in regenerative medicine Jöns Hilborn Materials Chemistry The Ångström Laboratory Uppsala University Sweden Outline Motivation for tissue regeneration Cell based approaches Material based
More informationNANO 243/CENG 207 Course Use Only
L13: Controlled Drug Delivery Systems May 17, 2018 Introduction & Definition Controlled drug delivery systems offer an approach to regulating both the duration and spatial localization of therapeutic agents.
More informationThe science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form.
The science of transforming an Active Pharmaceutical Ingredient (API) into a Drug Product (DP) in a specific dosage form. Three major needs that the formulation into a specific dosage form directly address
More informationFuture Areas of Technology Convergence
Future Areas of Technology Convergence Dr J Malcolm Wilkinson Managing Director Technology For Industry Ltd Cambridgeshire, UK Medilink Yorkshire & Humberside, 8 December 2005 1 Technology For Industry
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationP08 P14 P19 TRANSDERMAL DELIVERY & MICRONEEDLES TRANSDERMAL DELIVERY USING NATURAL MOISTURISING FACTOR COMPONENTS
P08 P14 P19 TRANSDERMAL DELIVERY USING NATURAL MOISTURISING FACTOR COMPONENTS HIGHLY CUSTOMISABLE HOLLOW POLYMER MICRONEEDLE SOLUTIONS SUCCESSFUL MASS PRODUCTION OF DISSOLVABLE MICRONEEDLE TECHNOLOGY TRANSDERMAL
More informationNUVEC. Non-viral adjuvant delivery system for vaccines and cancer treatments. Allan Hey, Head of CMC, N4 Pharma Ltd
NUVEC Non-viral adjuvant delivery system for vaccines and cancer treatments Allan Hey, Head of CMC, N4 Pharma Ltd 1 N4 Pharma plc o Established in 2014 o Listed on Alternative Investment Market (AIM) in
More informationPPS (Human) ELISA Kit
PPS (Human) ELISA Kit Cat. No.:DEIA4080 Pkg.Size:96T Intended use Immunoassay for quantitative determination of the content of Pentosan Polysulfate (PPS) in human plasma General Description Pentosan Polysulfate
More informationTHE INNOVATION COMPANY HEALTH. Institute for Biomedicine and Health Sciences
THE INNOVATION COMPANY HEALTH Institute for Biomedicine and Health Sciences Our central activity is innovative applied research that bridges the gap between basic research and industrial applications.
More informationIssues Related to the Formulation and Delivery of Pharmaceutical Proteins
Issues Related to the Formulation and Delivery of Pharmaceutical Proteins Pretoria16 August Prof. dr. Daan J.A. Crommelin Dept. Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, UIPS Scientific
More informationModel-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017
Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 Biopharmaceutical Classification System Approximately 80% of drugs in the pharmaceutical compounds
More informationThiolatedpoly(aspartic acid) polymers in ophthalmic therapy
Thiolatedpoly(aspartic acid) polymers in ophthalmic therapy Gabriella Horvát 1, Benjámin Gyarmati 2, Barnabás Szilágyi 2, András Szilágyi 2, Szilvia Berkó 1, Erzsébet Csányi 1,Piroska Szabó-Révész 1, GiuseppinaSandri
More informationCHAPTER 4 CONCLUSIONS AND FUTURE PERSPECTIVES
CHAPTER 4 CONCLUSIONS AND FUTURE PERSPECTIVES Wound infections are the major challenges in the wound care management. Infection can be either due to microbial attack or due to some diseases. This infection
More informationYOUR SOLUTION FOR SUCCESSFUL INTRADERMAL DELIVERY
YOUR SOLUTION FOR SUCCESSFUL INTRADERMAL DELIVERY In this article, Paul Vescovo, PhD, Project Manager, and Laurent-Dominique Piveteau, PhD, MBA INSEAD, Chief Operating Officer, both of Debiotech, discuss
More informationDan WU. Department of Biopharmaceutics, Kyoto Pharmaceutical University
Improvement of transdermal delivery of sumatriptan succinate using novel water emulsion patch or self-dissolving microneedle array, and their in vitro and in vivo characterizations Dan WU Department of
More informationChapter 1. Introduction
Chapter 1 Introduction Controlled drug delivery systems, which are intended to deliver drugs at predetermined rates for predefined periods of time, have been used to overcome the shortcomings of conventional
More informationUNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERSITATEA. Eman ta zabal zazu ESCUELA SUPERIOR DE INGENIEROS DE BILBAO BILBOKO INGENIARIEN GOI ESKOLA
UNIVERSIDAD DEL PAÍS VASCO / EUSKAL HERRIKO UNIBERSITATEA Eman ta zabal zazu ESCUELA SUPERIOR DE INGENIEROS DE BILBAO BILBOKO INGENIARIEN GOI ESKOLA LOW DIMENSIONAL SYSTEMS NANOROBOTS Master in Nanoscience
More informationPublic Assessment Report Scientific discussion. Novavita (cyanocobalamin) SE/H/1577/01/DC
Public Assessment Report Scientific discussion Novavita (cyanocobalamin) SE/H/1577/01/DC This module reflects the scientific discussion for the approval of Novavita. The procedure was finalised on 2017-01-27.
More informationApproaches to Nanoparticle Targeting. Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology
Approaches to Nanoparticle Targeting Mahmoud R. Jaafari, PhD Prof. of Pharmaceutics and Pharmaceutical Nanotechnology Principles of drug targeting Drug targeting is the systemic or local administration
More informationSupplementary Figure S1. Swelling and mechanical properties as a function of the PS-b- PAA block copolymer composition. a, Swelling kinetics of PAA
Supplementary Figure S1. Swelling and mechanical properties as a function of the PS-b- PAA block copolymer composition. a, Swelling kinetics of PAA homopolymer and PS-b-PAAs (4 mm disc with 1 mm thickness)
More informationWe make drugs smarter
We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities
More informationAdvanced Biomaterials and Nanotechnologies in Drug Delivery
NANOTECHNOLOGY & ADVANCED MATERIALS SYMPOSIUM Advanced Biomaterials and Nanotechnologies in Drug Delivery Date : 25 September 2015 (Friday) Time : 2:00pm 5:00pm (Registration starts at 1:45pm) Venue :
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationEvonik Birmingham Laboratories
Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationGuideline for Bioequivalence Studies of Generic Products. December 22, 1997
Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products
More informationELISA IMMUNOASSAY FOR DISEASE DETECTION
Unit 6/ Module 1 /Version B pg. 1 California Lutheran University s Enriched Science (CLUES) and California State University Program for Education and Research in Biotechnology (C-SUPERB) ELISA IMMUNOASSAY
More informationAbstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2
Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationQuarterly Report for the Period Ended 31 March 2018
Quarterly Report for the Period Ended 31 March 2018 Highlights Cash receipts of $617,440 received during the March quarter. Main royalty contributors were the SK-II Power Booster (throughout Asia) and
More informationOral Delivery of Drugs
Oral Delivery of Drugs 1 S E S S I O N O N E O F T I P P R O J E C T Advantages of taking oral drugs Convenient (storage, portability, premeasured dose) economical non-invasive, often safer route requires
More informationNanomedicine for Improved Efficacy of Tuberculosis Drugs Pharmacokinetic importance
Nanomedicine for Improved Efficacy of Tuberculosis Drugs Pharmacokinetic importance Emerging Researcher Symposium Dr. Rose Hayeshi 10 October 2012 Outline Challenges in TB treatment Nanomedicine as proposed
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationAntibody Discovery at Evotec
Antibody Discovery at Evotec - Overview - Evotec Antibodies Adding value to our partners research Innovative and flexible solutions from target ID to pre-clinical candidate The people A wide therapeutic
More informationThe research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass
212 9. Summary, conclusion and recommendation 9.1 Summary and conclusion The research work highlights the development and evaluation of novel transbuccal drug antagonist of Famotidine. route have a rapid
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/32775/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL
More informationPaving the way for Non-Clinical Bioanalytical Partnerships Louise Angell
Paving the way for Non-Clinical Bioanalytical Partnerships Louise Angell Content Overview of non-clinical immunogenicity testing for biologics Regulatory guidance Bioanalytical considerations Risk based
More informationL Intérêt du Projet CTI
L Intérêt du Projet CTI Prof. Yogeshvar N. Kalia Molecular Therapeutics Delivery Group Section des sciences pharmaceutiques CMU, 1 Rue Michel Servet, Genève Email: yogi.kalia@unige.ch REUSSIR VOS PROJETS
More informationDermal drug testing. Pharmacokinetic, pharmacodynamic and bioequivalence studies in the dermis
Dermal drug testing Pharmacokinetic, pharmacodynamic and bioequivalence studies in the dermis FOTOLIA, www.isselee.com Photo : FOTOLIA, Vlad Gansovsky FOTOLIA, Vitaliy Pakhnyushchyy We investigate the
More informationAntibody against Chikungunya virus (mrna-1944)
Antibody against Chikungunya virus (mrna-1944) Modality Program # Program Indication Preclinical development Phase 1 Phase 2 Phase 3 and commercial Moderna rights mrna-1944 Antibody against Chikungunya
More informationVACCINE DELIVERY USING THE NEMAURA SOLID DOSE INJECTOR
VACCINE DELIVERY USING THE NEMAURA SOLID DOSE INJECTOR In this article, Joanne Broadhead, PhD, Product Development, Nemaura Pharma; and Karmen Cheung, MSc, Department of Chemical Engineering, Loughborough
More informationComplete kit for the systematic 3-D conformational comparability analysis of Simponi biosimilar molecule to Golimumab (Simponi trade name).
GoliBridge ELISA Kit 1 Plate Kit Catalog # AB000215 Complete kit for the systematic 3-D conformational comparability analysis of Simponi biosimilar molecule to Golimumab (Simponi trade name). Please read
More informationBioprinting at the Naval Research Laboratory. Bradley Ringeisen, Ph.D. Head, Bioenergy and Biofabrication Section Chemistry Division
Bioprinting at the Naval Research Laboratory Bradley Ringeisen, Ph.D. Head, Bioenergy and Biofabrication Section Chemistry Division 1 What is bioprinting? Bioprinting is the controlled deposition of any
More informationPharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents
More informationIda Lepistö Helsinki-Kuopio pendolino
Ida Lepistö Helsinki-Kuopio pendolino 25.10.2017 OBJECTIVES What are polymer therapeutics? Why and how to conjugate drugs with polymers? How polymer conjugation can affect ADME-properties? in the end there
More informationT ransdermal Drug Delivery Systems
Register by January 1 st and receive a $300 Discount! PharmaED s T ransdermal Drug Delivery Systems E x a m i n e R e c e n t D e v e l o p m e n t s i n Tra n s d e r m a l D r u g D e l i v e r y FEBRUARY
More informationImmunology 101: Implications for Medical Device Failure. Joshua B. Slee, PhD Assistant Professor of Biology
Immunology 101: Implications for Medical Device Failure Joshua B. Slee, PhD Assistant Professor of Biology Learning Goals Understand innate and adaptive immunity Explain how innate and adaptive immunity
More informationEvaluation of Clindamycin encapsulated in PLA/PLGA nanoparticles
Evaluation of Clindamycin encapsulated in PLA/PLGA nanoparticles Presented by Dr. Bismita Nayak bismita.nayak@gmail.com, nayakb@nitrkl.ac.in Department of Life science National Institute of Technology
More informationINACTIVE INGREDIENTS DATABASE AND EMERGING DOSAGE FORMS. ExcipientFest 2016
INACTIVE INGREDIENTS DATABASE AND EMERGING DOSAGE FORMS ExcipientFest 2016 1 Presented by Meera Raghuram Manager, Global Regulatory Affairs and Strategies Lubrizol LifeSciences Chair Regulatory Affairs
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/94528/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE
More informationINTRODUCTION 1. INTRODUCTION
1. INTRODUCTION Helicobacter pylori (H. pylori) is reported to be an important etiologic factor in the development of the gastritis, gastric ulcer and gastric carcinoma in human stomach (Marshall and Warren,
More informationVELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS
VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS Dr Mikael Bjerg Caspersen Industrial Biotechnology Conference August 10 th 2015 INNOVATIVE TECHNOLOGY
More informationGuideline for Bioequivalence Studies of Generic Products for Topical Use. July 7, 2003
Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 003 1 Content Chapter 1. Introduction Chapter. Terminology Chapter 3. Test I. Reference and test products II. Bioequivalence
More informationIssued: 02/23/06 Spring 2006 Due: 03/02/ points total
Problem Set 2 Model Solutions 20.462J/3.962J Issued: 02/23/06 Spring 2006 Due: 03/02/06 100 points total 1. From the reading for lecture 4 (Kumamoto et al., Nat. Biotech. 20, 64-69 (2002)), we saw an example
More informationPRIME-XV T CELL CDM. Chemically-defined, animal component-free medium for T cell culture
T CELL CDM Chemically-defined, animal component-free medium for T cell culture Chemically-defined, animal component-free formula delivers optimal performance Optimized to support vigorous growth while
More informationBioPhysics Assay Laboratory, Inc. ٠ 80 Webster Street ٠ Worcester MA ٠ Phone (508) ٠ Fax (508) ٠
Introduction In this report, we describe and present the performance characteristics of an immunoassay (ELISA) method to measure the concentration of iohexol in collected samples to obtain a mgfr value.
More informationRegulatory Challenges for the Licensure of Future Vaccines
Regulatory Challenges for the Licensure of Future Vaccines Tong Wu, Ph.D. Bacterial & Combination Vaccine Division, BGTD, Health Canada June 26-29, 2018, Seoul, Korea, the Global Bio Conference 1 Disclaimer
More informationChallenges in receptor occupancy determination assays by flow cytometry in drug development
Challenges in receptor occupancy determination assays by flow cytometry in drug development DATE 17 November 2016 PRESENTED BY Martine Broekema, Ph.D. Associated Director of Bioanalytical Sciences Large
More informationMASTER IN PHARMACEUTICAL SCIENCES (Thesis Track)
MASTER IN PHARMACEUTICAL SCIENCES (Thesis Track) I. GENERAL RULES CONDITIONS: Plan Number 1 \ 12 70 2005 T 1. This plan conforms to the valid regulations of the programs of graduate studies. 2. Areas of
More informationHealthcare. Healthcare. The Centre for Process Innovation. From innovation to commercialisation
Healthcare Healthcare The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation (CPI)
More information1 Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
In-Vitro Skin Permeation and Biological Evaluation of Lornoxicam Monolithic Transdermal Patches Mohamed El Nabarawi 1, Dalia S Shaker 2*, Dalia A Attia 3, Shereen A Hamed 2 1 Department of Pharmaceutics
More informationIN VITRO CHARACTERZATIOAN AND EVALUATION OF TRANSDERMAL DRUG DELIVERY SYSTEM FOR METOPROLOL TARTARATE DR.B.ANILREDDY
JPRHC Research Article IN VITRO CHARACTERZATIOAN AND EVALUATION OF TRANSDERMAL DRUG DELIVERY SYSTEM FOR METOPROLOL TARTARATE DR.B.ANILREDDY For author affiliations, see end of text This paper is available
More information7th Annual Shanghai Symposium on Clinical and Pharmaceutical Solutions through Analysis
Mechanistic Physiological PhysioPD Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach Sharan A Pagano SVP, Scientific Alliances at Rosa & Co. LLC 7th Annual Shanghai
More informationIn silico tools to study food-drug interactions, an Industry Perspective
Paris, April 4th, 2018 Physiologically Based PharmacoKinetic modeling (PBPK): A new Paradigm in Drug Development In silico tools to study food-drug interactions, an Industry Perspective Neil Parrott, Pharmaceutical
More informationQUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS
QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October
More informationLETI-HEALTH. Adrienne Pervès Deputy Director LETI Technologies for Biology and healthcare Department
Adrienne Pervès adrienne.perves@cea.fr Deputy Director LETI Technologies for Biology and healthcare Department LETI-HEALTH Micro- NanoTechnologies for Healthcare and Biology MISSION AND EXPERTISE Focused
More informationCHAPTER INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES
1.0 INTRODUCTION 1.1 ORAL DRUG DELIVERY: SCOPE AND ADVANTAGES Oral ingestion is the preferred route for administration of therapeutic agents, providing a convenient method of effectively achieving both
More informationSupplementary Figure 1.
9 8 5 6F12 IgG2a Isotype Control 5 1 15 Supplementary Figure 1. Passive treatment with isotype control mab does not affect viral challenge. Wild type mice were treated with 4 mg/kg of mouse IgG2a 6F12
More informationTransdermal Drug in Adhesive Delivery Patch
Transdermal Drug in Adhesive Delivery Patch A Technology Outline CC Lee M.Sc.,B.Sc.(Hons) CEO, Director of Technology Transdermal Drug Delivery Offers the Best of IV and Oral Administration IV Oral TDD
More informationCloudbreak: Antibody-Drug Conjugates for Treatment of MDR Gram-Negative Bacterial Infections
Cloudbreak: Antibody-Drug Conjugates for Treatment of MDR Gram-Negative Bacterial Infections James C. Levin, Ph.D. Director of Preclinical Development Discovery on Target Conference September 26, 2018
More informationMonoclonal Antibody Generation. Ivo Lorenz Tri-Institutional Therapeutics Discovery Institute
Monoclonal Antibody Generation Ivo Lorenz Tri-Institutional Therapeutics Discovery Institute Common Antibody Formats Heavy chain VL VH Light chain Fab CL CH1 VH VL Linker CH2 VH VL Fc CH3 IgG Immunoglobulin
More informationChE 125. Principles of Bioengineering
ChE 125 Principles of Bioengineering ChE 125 Instructor: Prof. Samir Mitragotri Room 3349, Engineering II Email: samir@engineering.ucsb.edu Office Hours: Tuesday 1-2 pm Teaching Assistant: Aaron Anselmo
More informationInterplay of Cells involved in Therapeutic Agent Immunogenicity. Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology
Interplay of Cells involved in Therapeutic Agent Immunogenicity Robert G. Hamilton, Ph.D., D.ABMLI Professor of Medicine and Pathology Disclosure The author works with Amicus on an immunogenicity project
More informationNew Hope For Serious Infections
New Hope For Serious Infections Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning
More informationBIOPHARMACEUTICS CLASSIFICATION SYSTEM-BASED BIOWAIVERS - M9
BIOPHARMACEUTICS CLASSIFICATION - M9 Step 2 document to be released for comments Date 7 June 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal
More informationConcept paper on the development of a guideline on quality and equivalence of topical products
1 2 3 4 5 6 7 8 2 December 2014 EMA/CHMP/QWP/558185/2014 Committee for Medicinal Products for Human use (CHMP) Concept paper on the development of a guideline on quality and equivalence of topical Draft
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationFentanyl (Human) ELISA Kit
Fentanyl (Human) ELISA Kit Catalog Number KA0931 96 assays Version: 06 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the
More informationDr. S. Harinarayana Rao
Dr. S. Harinarayana Rao Theatre, Indian Habitat Centre, New Delhi July 30 31, 2013 Introduction Classification ICH 6 guidelines Innovative methods RCGM and EMEA Challenges Conclusion What is a biopharmaceutical
More informationETP & em-patch Test and Evaluation Summary
Active transdermal drug delivery OBJ ETP & em-patch Test and Evaluation Summary 1 BACKGROUND OBJ Limited is an Australian drug delivery company focused on the development and commercialization of magnetic
More informationCHAPTER 4. Milestones of the drug discovery
CHAPTER 4 Milestones of the drug discovery 4.Milestones of the drug discovery: Highlights the importance of the below critical milestones of the drug discovery and correlated to the current research. 1.
More informationInfectious Disease Programs:
Infectious Disease Programs: Valortim (MDX-133) Fully Human Anti-Anthrax Toxin MAb Candidate for Project BioShield Procurement Israel Lowy, M.D., Ph.D. Senior Director, Clinical Science and Infectious
More informationFirst UNGAP meeting Food-Drug Interactions Regulatory Aspects
First UNGAP meeting Food-Drug Interactions Regulatory Aspects Leuven, 09 March 2018 Dr. Henrike Potthast HPt COST meeting, Leuven, BE 09 March 2018 Page 1 Disclaimer The presentation reflects the personal
More informationnanoprecipitation mpeg-pla 2 nd Emulsion mpeg-pla in DCM
THERAPEUTIC NANOTECHNOLOGY LAB MODULE Location: BioNano Lab, 3119 Micro and Nanotechnology Laboratory (MNTL) Instructor: Jianjun Cheng, Assistant Professor of Materials Science and Engineering Lab Assistants:
More informationSingapore nanotechnology combats fatal brain infections
P ublic release date: 28-Jun-2009 Contact: Cathy Yarbrough sciencematter@yahoo.com 858-243-1814 Agency for Science, Technology and Research (A*STAR), Singapore Singapore nanotechnology combats fatal brain
More informationBiopharmaceutics Applications in Drug Development
Biopharmaceutics Applications in Drug Development Edited by Rajesh Krishna Merck & Co., Inc. Rahwav, NJ. USA and Lawrence Yu Center for Drug Evaluation & Research Rockville, MD, USA 4y Springer Contents
More informationNOVEL DRUG DELIVERY SYSTEMS II
NOVEL DRUG DELIVERY SYSTEMS II Polymer Science 1. Define Polymer. Describe its properties. 2. Classify polymers based on various criteria. 3. What are the ideal characteristics of biodegradable polymers?
More informationImmunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals
Immunogenicity: Assessing the Clinical Relevance and Risk Minimization of Antibodies to Biopharmaceuticals Daniel Kramer/Kathleen Beach Need for public-private collaboration 1 All biopharmaceuticals are
More informationDIFFERENT APPROACHES FOR IMPROVING SKIN ACCUMULATION OF CLOBETASOL-17-PROPIONATE
DIFFERENT APPROACHES FOR IMPROVING SKIN ACCUMULATION OF CLOBETASOL-17-PROPIONATE Taner ŞENYİĞİT*, Cristina PADULA**, Özgen ÖZER*, Patrizia SANTI** *Ege University, Faculty of Pharmacy, Department of Pharmaceutical
More information1. National Health Institute, National Cancer Institute, R01 Title: Nanotechnology enabled targeting of p53 deficiency in human cancer
1. National Health Institute, National Cancer Institute, R01 Title: Nanotechnology enabled targeting of p53 deficiency in human cancer Duration: 2016.7-2021.6 Total amount: $1,808,042 Investigators: Xiaoming
More informationRadiation engineering - on the fast track towards the development of smart nanodrugs Clelia Dispenza
Radiation engineering - on the fast track towards the development of smart nanodrugs Clelia Dispenza Università degli Studi di Palermo, Italy The nanotechnology revolution in drug delivery Stable and durable
More informationInjectable modified release products
Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the
More informationUNIVERSITY OF ROME LA SAPIENZA NANOTECHNOLOGIES ENGINEERING NANOPARTICLES IN BIOMEDICINE
UNIVERSITY OF ROME LA SAPIENZA NANOTECHNOLOGIES ENGINEERING NANOPARTICLES IN BIOMEDICINE Challenges The challenges are: in-situ analysis and in vivo at micro level recognize biomolecules functionality
More information"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia
"From Bedside to Bench and Back: regulatory requirements for collaborations between pharma industry and academia Damir Hamamdžić D.V.M., Ph.D. Office of Research Regulatory Affairs Rutgers University RWJMS
More informationADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH
ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH Faculty of Pharmaceutical Sciences Chulalongkorn University Industrial pharmacy is a discipline which includes manufacturing, development,
More informationNanosize: What Can We Learn about Nonclinical Evaluations? Abby Jacobs CDER/FDA 1/2014 NOT official CDER/FDA policy
Nanosize: What Can We Learn about Nonclinical Evaluations? Abby Jacobs CDER/FDA 1/2014 NOT official CDER/FDA policy The Interplay Between Characterization and Toxicology (a) How do we know the material
More information